| Product NDC: | 0179-0091 |
| Proprietary Name: | FENOFIBRATE |
| Non Proprietary Name: | FENOFIBRATE |
| Active Ingredient(s): | 160 mg/1 & nbsp; FENOFIBRATE |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0179-0091 |
| Labeler Name: | KAISER FOUNDATION HOSPITALS |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA076509 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20110426 |
| Package NDC: | 0179-0091-80 |
| Package Description: | 2160 TABLET in 1 BOTTLE (0179-0091-80) |
| NDC Code | 0179-0091-80 |
| Proprietary Name | FENOFIBRATE |
| Package Description | 2160 TABLET in 1 BOTTLE (0179-0091-80) |
| Product NDC | 0179-0091 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | FENOFIBRATE |
| Dosage Form Name | TABLET |
| Route Name | ORAL |
| Start Marketing Date | 20110426 |
| Marketing Category Name | ANDA |
| Labeler Name | KAISER FOUNDATION HOSPITALS |
| Substance Name | FENOFIBRATE |
| Strength Number | 160 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Peroxisome Proliferator Receptor alpha Agonist [EPC],Peroxisome Proliferator-activated Receptor alpha Agonists [MoA],PPAR alpha [Chemical/Ingredient] |